

McDowell, Robert

From: Chrissy Fohr <CFohr@LKNPainAndWeight.com>
Sent: Thursday, November 30, 2017 9:41 PM
To: Henderson, Meredith
Subject: [External] WC draft rules opioid management

CAUTION: External email. Do not click links or open attachments unless verified. Send all suspicious email as an attachment to report.spam@nc.gov.

Hi Meredith,

My name is Chrissy Fohr. I'm a nurse practitioner specializing in pain. I am giving my feedback on the draft rules for utilization of opioids in the treatment of WC patients. The rules look pretty good so far. I do have a concern with the section covering "both the acute phase and the chronic phase of pain treatment". The last bullet says, "a provider may not prescribe transcutaneous, transdermal, transmucosal, or buccal opioid preparations without documentation in the medical record that oral opioids are inadequate. An exception should be considered for the use of Butrans (transdermal) and/or Belbuca (buccal) in the chronic phase of treatment. Both agents have low MME compared to oral agents, have less potential for abuse/misuse, and treat muscle type pain better than any oral opioid available. These agents are schedule III not schedule II like most oral options and have little to no street value. This is a good option for those patient who have a risk factors for misuse, abuse and/or addiction or have a history of substance use disorders. I am glad to discuss this further if needed. Have a great day.

Chrissy Fohr, NP
Lake Norman Pain and Weight Management

Sent from my iPad